The buildup of beta amyloid in the brain can lead to the degeneration of neurons and is one of several markers implicated in the development of Alzheimer's Disease (AD). Currently, AD is typically confirmed by identifying the presence of tissue markers, including beta amyloid plaques, in post-mortem brain samples. Use of targeted imaging agents may help physicians detect amyloid deposition in live humans.
"These results should provide encouragement for patients and clinicians about the value of amyloid imaging in diagnosing AD," said Jonathan Allis, MI PET Segment Leader, GE Healthcare Medical Diagnostics. "Use of PET imaging scans to detect AD pathology may enable physicians to make a more accurate and earlier diagnosis of the disease."
Data highlights from three clinical abstracts featured at the 2011 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Paris suggest that:
- Flutemetamol reader training provided a highly consistent method for interpreting PET images. Readers blinded to clinical information demonstrated high inter- and intra-reader agreement rates when interpreting the brain distribution of Flutemetamol as normal and abnormal images.
- Flutemetamol imaging was consistent with the understanding that normal pressure hydrocephalus (NPH), a progressive condition associated with dementia, gait abnormalities and urinary incontinence, represents a heterogeneous population with evidence of AD pathology.
- 6-CN-Flutemetamol is comparable to 6-CN-Pittsburgh Compound-B (PiB) in its ability to bind to beta amyloid in vitro.
[18F]Flutemetamol is one part of a broad portfolio of diagnostic solutions that GE Healthcare is currently developing in the Alzheimer's field. The company is taking a comprehensive approach to understanding AD through its ongoing research to uncover the causes, risks and physical effects of the disease. GE Healthcare's global commitment to advance clinical knowledge and provide a variety of technologies to aid the fight in this epidemic may assist physicians in the acceleration of diagnosis and improvement of treatment decisions in all stages of the disease. The company already offers a range of imaging modalities used by physicians to assist in the detection of AD and dementia (CT, MRI, PET, SPECT) and has been a key contributor to the Alzheimer's Disease Neuroimaging Initiative since its inception. GE Healthcare also plays a key role in PredictAD, an EU-funded research project to develop solutions to enable earlier diagnosis of AD.
Edelman Public Relations